City of Hope cancer treatment, page-16

Big Pharma often have "rules" or at least policies about the stages at which they will attempt to buy new technologies.
It's about risk management and its based on past experience.
They would rather pay 10x the price for proven technology than early stage technology because experience (bitter experience) has proven buying too early comes at vastly increased risk of investing in promising technology that hits a show stopper.

They tend to wait for start-ups like IMU to do the heavy lifting of developing and proving-up the technology and working through FDA approvals before stepping-in.

But, there are many variants to this approach including buying an option (first right of refusal) to later purchase/buy a license which enables them to put a foot on the technology without going all-in. However, IMU is not cash starved so this insulates them from having to accept such a deal.

So I am guessing all the Big Pharma usual suspects are fully aware of IMU and are tracking the developments but none of the technologies tick all the boxes (yet).

There is also a big difference between running a biotech R&D company and running a pharmaceutical manufacturing and distribution company.
And competing against the might of established global behemoths is not good business.
I doubt IMU will risk attempting to make the transition and will likley license the technology to one of the majors.

Just my thoughts.
I have no idea really.